Medifirm Intelledge Global · Pharmaceutical Intelligence Platform
A consulting-grade pharmaceutical intelligence platform with 76K+ drug records, 25 interactive analytics dashboards, and AI-powered insights across the entire drug development lifecycle — from pipeline tracking to patent cliffs, regulatory landscape, Gantt timelines, heatmaps, market forecasts, and white space identification.
Our database is not an automated pull from a single API feed. It is a carefully compiled intelligence asset — built and updated manually by our research team using primary research, healthcare networks, chemist networks, and other trusted field sources to ensure accuracy and completeness.
Our drug database is a comprehensive pharmaceutical intelligence platform that goes far beyond a simple searchable list. It powers 25 specialized analytics dashboards, each designed to answer specific strategic questions across the drug development lifecycle — from competitive landscape analysis to Gantt timelines, heatmaps, market forecasts, leads analysis, and AI-powered executive reporting.
Comprehensive global pharmaceutical database covering approved and pipeline drugs across 190+ markets.
Filter by drug name, brand, molecule, generic name, company, therapy area, disease, mechanism, target, drug class, phase, regulatory status, country, biomarker, and more.
Multi-dimensional filtering with real-time search across all key fields. Save and share filtered views with your team.
Export filtered drug records to Excel or CSV for offline analysis, reporting, and integration with your internal tools.
Built-in duplicate detection and management system that identifies and helps remove redundant records based on composite key matching.
Comprehensive regulatory data including approval dates, application numbers, and regulatory identifiers for every drug record.
25 intelligence modules with structured data outputs for integration with your workflows, dashboards, and internal systems.
7 AI-powered analytics modules including drug similarity, portfolio benchmarking, forecasting, gap analysis, licensing radar, and executive reporting. Plus 6 advanced analytical modules: Gantt timelines, time-to-market, heatmaps, market forecast, leads analysis, and opportunity assessment.
Each module is a purpose-built analytics dashboard with interactive charts, tables, and AI-powered insights. Filter by therapy area, company, country, phase, mechanism, or target to drill down into specific segments.
Bird's-eye view of the global pharmaceutical landscape with KPIs for approved drugs, pipeline counts, new regulatory approvals, patent expiries, orphan drugs, advanced therapies, biosimilars, market concentration (HHI), and data quality metrics.
Per-company breakdown of marketed drugs, pipeline assets, therapy area focus, mechanism of action, and patent cliff exposure. Market share analysis with Herfindahl-Hirschman Index (HHI) for competitive landscape assessment.
Deep dive into each therapeutic area with approved drug counts, pipeline by phase (I–III + Registration), top companies, mechanisms, targets, biomarkers, and recent launch activity.
Mechanism of Action intelligence with per-mechanism drug counts, approved vs. pipeline split, associated companies, and disease indications. Identify which mechanisms are crowded vs. emerging.
Drug target analysis with per-target drug counts, approval status, pipeline activity, and company landscape. Identify validated vs. emerging targets and competitive intensity.
Biomarker landscape analysis with per-biomarker drug counts, approval status, pipeline activity, associated companies, and disease indications. Track precision medicine trends.
Interactive Sankey diagram showing drug development flow from Early Phase I through Phase IV and Approval. Funnel analysis with attrition rates by phase and pipeline progression percentages.
Patent expiry timeline by year, top blockbuster loss-of-exclusivity (LOE) opportunities, and company exposure to patent cliffs. Identify generics and biosimilar opportunities.
Regulatory approval counts, approval trends by year, regulatory status distribution, license types, licensure status, and route of administration breakdown.
Country-level analysis with approved drug counts, pipeline activity, and top companies per market. Understand geographic drug distribution and market presence.
Disease-level opportunity scoring based on approved drugs, pipeline activity, company count, and advanced therapy presence. Identifies high-opportunity disease areas.
Identifies underserved disease areas with few approved drugs but pipeline activity — representing high unmet need and innovation white space. Advanced therapy (ATMP) gap analysis included.
AI-powered drug similarity search to find structurally or mechanistically similar drugs. Useful for drug repurposing, biosimilar tracking, and competitive positioning.
Compare two companies side-by-side across portfolio size, pipeline depth, therapy area focus, mechanism diversity, and patent exposure. AI-generated competitive assessments.
AI-powered pharmaceutical market forecasting using historical approval trends, pipeline progression rates, and patent expiry data to project future market dynamics.
AI-powered analysis to identify gaps in a company's drug portfolio — missing therapy areas, underrepresented mechanisms, and untapped target opportunities.
AI-powered licensing opportunity identification — detect drugs with approaching patent expiries, pipeline assets seeking partners, and in-licensing/out-licensing opportunities.
Track the full lifecycle of drugs from discovery through approval, launch, patent expiry, and loss of exclusivity. Lifecycle stage distribution and timeline analysis.
Interactive Gantt chart visualizing drug development lifecycles from approval through patent expiry. Zoom, scroll, and explore timeline durations for up to 50 drugs with detailed lifecycle breakdowns.
Box plot analysis of years from launch to approval by therapy area. Statistical breakdown showing avg, min, median, and max time-to-market, with approval year trend analysis and therapy area ranking.
Two interactive heatmaps: Therapy Area × Development Phase and Company × Therapy Area. Visual density matrices showing drug concentration across dimensions with color-coded intensity.
Data-driven 5-year market projections based on historical approval CAGR. Combined historical + forecast chart, projected market share by therapy area, confidence-rated predictions, and pipeline attrition modeling.
Company lead scoring with tier classification (Tier 1/Emerging). Composite score based on pipeline strength, therapy diversity, mechanism diversity, and patent risk. Bubble scatter and pipeline ratio analysis.
6-dimensional radar chart comparing pipeline, approved, companies, mechanisms, targets, and recent launches across therapy areas. Opportunity index ranking and opportunity-vs-saturation matrix.
Generate comprehensive AI-powered executive reports summarizing the entire analytics dashboard — key findings, strategic insights, and actionable recommendations.
Every drug record in our database contains up to 40+ structured fields, enabling precise filtering, cross-referencing, and multi-dimensional analysis.
Our cross-reference data links RxNorm RXCUIs to DailyMed SPL Set IDs, enabling seamless navigation between clinical nomenclature and FDA-approved drug labels. With 71K+ RxNorm-linked records and 39K+ DailyMed-linked records, this mapping powers interoperability across EHR systems, formulary tools, and regulatory workflows.
Each drug record includes both RxNorm clinical nomenclature data and DailyMed FDA label data. The SPL Set ID and RXCUI are linked together, creating a unified reference that connects clinical vocabularies to regulatory documents.
Clinical Nomenclature (NLM)
FDA Drug Labels (NLM)
Map medication lists using RxNorm codes to FDA-approved drug labels via SPL Set IDs. Enables clinicians to pull boxed warnings, labeler info, and packaging details directly from within EHR workflows.
Cross-reference adverse event reports (coded with RXCUIs) to the exact SPL document version. Track boxed warning changes across label updates and link safety signals to specific manufacturer labels.
Align formulary systems (RxNorm-based) with drug catalog systems (SPL-based) to ensure consistent drug identification across procurement, dispensing, and billing workflows. Eliminate ambiguity in drug selection.
Identify drugs with existing SPL labels that have RxNorm concepts in new therapy areas. Track label expansions by comparing SPL version history against RxNorm concept updates.
Automatically flag drugs with FDA boxed warnings (from SPL data) in medication lists identified by RxNorm codes. Push real-time alerts when labels are updated with new safety warnings.
Query SPL ↔ RxNorm mappings by SPL Set ID or RXCUI with structured JSON responses. Full CRUD operations available for integration with your internal systems and workflows.
Every drug record includes linked RxNorm & DailyMed SPL data for comprehensive clinical and regulatory intelligence
A visual walkthrough of the drug database interface and analytics dashboard modules available after login.
Every drug in our database has a comprehensive master file with 10 specialized intelligence tabs. Each tab provides a different lens through which to analyze a drug — from clinical development and regulatory history to patent landscapes, market intelligence, competitive positioning, scientific publications, AI-powered insights, company profiling, and disease burden epidemiology.
Drug master profile with 19+ identification fields, regulatory designations, black box warnings, indications, and safety issues
Complete clinical trial registry with trial IDs, phases, enrollment, countries, start dates, and trial statuses
Regulatory approval history across agencies with application types, application numbers, approval dates, and notes
Patent portfolio with patent numbers, types, jurisdictions, filing/grant/expiry dates, and patent status tracking
Market forecasts, pricing by country, licensing deals with deal types, values, licensors, licensees, and statuses
Competitive landscape with competitor relationships, biosimilar tracking, approval status, and launch status monitoring
Scientific publication library with 50+ recent publications per drug, including dates, journals, and abstracts
AI-generated strategic insights and adverse event tracking with report dates, severity, and outcomes
Linked company profile with originator details, company type, country, and direct navigation to full company intelligence
Epidemiology data including prevalence, incidence, mortality, DALYs, risk factors, age/gender distribution, and global rankings
Keytruda · Merck & Co.
Each drug record in the database is linked to its comprehensive master file in Drug Intelligence. Click any drug to dive into its 360° profile with 10 tabs of detailed intelligence.
Each drug master file links directly to its company profile with financial data, stock performance, competitive benchmarking, quarterly results, investor intelligence, and economic indicators.
Each drug is linked to its disease burden profile with epidemiology data including prevalence, incidence, mortality, DALYs, risk factors, age/gender distribution, and global disability rankings.
Each company in our database has a comprehensive profile with 9 intelligence tabs covering financial data, stock performance, quarterly results, investor intelligence, economic indicators, competitive benchmarking, drug pipeline, news, and admin editing capabilities.
Company profile with ticker, exchange, country, type, website, description, and key financial metrics
Live stock price, market cap, P/E, EPS, dividend yield, beta, 52-week range, shares outstanding, and trading volume
Quarterly revenue, gross profit, operating income, net income, EBITDA, R&D expenditure, and revenue trend bar charts
Dividend information, stock performance, analyst estimates, share information, and key financial ratios
Macroeconomic indicators including interest rates, CPI, GDP, treasury yields, and unemployment data with historical charts
Side-by-side comparison of pharma companies across price, market cap, P/E, revenue, EBITDA, margins, growth, and beta
All drugs marketed and originated by the company with direct links to each drug master file
Latest company news and press releases aggregated from multiple sources
Admin-only editing capability for company profile fields including name, ticker, country, type, website, and description
| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | R&D |
|---|---|---|---|---|---|
| 2023 | $58.5B | $42.1B | $21.3B | $21.2B | $5.8B |
| 2022 | $100.3B | $72.5B | $43.2B | $31.4B | $11.4B |
| 2021 | $81.3B | $56.2B | $28.1B | $22.0B | $5.3B |
Export complete company financial data in CSV or Excel format directly from the company profile page. Downloads include company overview, stock data, annual and quarterly financial reports, balance sheet, cash flow, dividends, splits, and historical price data — all in a single formatted file.
Every drug in our database is linked to its disease burden profile, providing epidemiology data including prevalence, incidence, mortality, DALYs, YLDs, YLLs, risk factors, age & gender distribution, global disability rankings, 5-year trends, and 2050 population forecasts. This enables data-driven market sizing, unmet need quantification, and therapeutic area prioritization.
Disease burden data showing epidemiology, mortality, DALYs, and risk factors globally.
Use prevalence and incidence data to estimate addressable patient populations and forecast drug demand by geography and demographic segment.
Quantify disease burden using DALYs, YLDs, and YLLs to identify high-unmet-need areas and prioritize R&D investments accordingly.
Track 5-year disease trends, rank changes, and 2050 population forecasts to anticipate future disease burden shifts and emerging market opportunities.
Our proprietary database covers 8603+ therapy areas, 16K+ diseases, and 8K+ companies across 3+ countries. Here's a visual snapshot of the intelligence depth available to our clients.
Drug records by approval status
Drug count by top therapy areas (anonymized)
Therapy area names are anonymized. Clients get full taxonomy access.
Designated drug records
Drug records across development stages
Drug records by major regulatory regions
Relational database with 40+ searchable fields, advanced filtering, and AI-powered insights
A step-by-step workflow guide for getting the most out of the platform — from basic search to advanced AI-powered analytics.
Navigate to /drug-database after logging in. The database loads with 20 records per page and shows total record count at the top.
Use the filter panel to narrow down by company, therapy area, disease, mechanism, target, phase, regulatory status, country, biomarker, and 10+ more dimensions. Multiple filters can be combined.
Click any drug row to see full details including all 40+ fields, custom enriched fields, attachments, and related records.
Select records and click "Export" to download filtered results as Excel (.xlsx) or CSV files for offline analysis.
Click "Analytics Dashboard" to open the 25-module analytics suite. The dashboard opens in a new tab with a sidebar navigation for all modules.
Navigate through the sidebar to explore Executive Intelligence, Competitive Intelligence, Pipeline Sankey, Patent & LOE, Gantt timelines, heatmaps, market forecasts, and more.
In AI-powered modules (Forecasting, Benchmarking, Gap Analysis, Licensing Radar, Executive Report), click "Generate" to get AI-powered strategic insights.
Use the Advanced Filters bar at the top of the analytics dashboard to filter by therapy area, company, country, phase, mechanism, or target. All modules update dynamically.
See how pharmaceutical teams use specific analytics modules to solve strategic challenges across the drug development lifecycle.
A BD team needs to know what their top 5 competitors are developing and when their patents expire.
Use the Competitive Intelligence module to see per-company pipeline vs marketed drugs, therapy area focus, and patent cliff exposure. Filter by company to drill down into specific competitors.
A licensing team needs to find drugs approaching patent expiry that could be in-licensed or acquired.
Use the Licensing Radar to detect drugs with approaching patent expiries, pipeline assets seeking partners, and AI-generated deal rationale for each opportunity.
A portfolio strategy team wants to identify underserved disease areas with high unmet need but low competition.
Use White Space Analysis to find diseases with few approved drugs but active pipeline development. Cross-reference with Opportunity Assessment radar to validate multi-dimensional opportunity.
A regulatory affairs team needs to benchmark their drug approval timeline against industry averages.
Use Time to Market Analysis to see avg/median/max years from launch to approval by therapy area. Compare against the Regulatory Intelligence module for approval trends across regulatory agencies.
A market access team is evaluating which countries to launch a new drug in first.
Use Geographic Intelligence to see country-level drug counts, approved vs pipeline ratios, and top companies per market. Combine with Heatmap Analytics for therapy × geography density.
An R&D team needs to identify which mechanisms and targets are emerging vs crowded.
Use MoA Analytics and Target Intelligence to see competitive density per mechanism/target. Use AI Drug Similarity to find repurposing candidates.
Our drug database is not a one-size-fits-all solution. We bucket our offerings to serve the unique needs of pharma, biopharma, biotech startups, biomedicines, EHR companies, and data-driven organizations — each with tailored intelligence modules, data fields, and workflow integrations.
Large pharmaceutical enterprises with established portfolios, global market presence, and complex competitive landscapes.
Biologics-focused organizations developing biosimilars, mAbs, and advanced biologic therapeutics across global markets.
Early-stage and emerging biotech companies seeking white space, target validation, and investor-ready competitive intelligence.
Organizations focused on precision medicine, biomarker-driven therapies, and personalized treatment approaches.
Electronic health record vendors, clinical decision support systems, and healthcare platforms needing standardized drug data interoperability.
Market research firms, data aggregators, consultancies, and analytics companies seeking comprehensive pharmaceutical data for downstream products and services.
Access 76K+ drug records and 25 analytics dashboards today. Login to explore the full database, generate AI insights, and export data.
Want a guided demo? Contact our team to schedule a walkthrough.